Histopathological evaluation of drug-induced liver disease

Drug-Induced Liver Disease

Volumn , Issue , 2013, Pages 241-263

  Kleiner, David E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Disease classification; Liver biopsy; Pathology

Indexed keywords

EID: 84882573481     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387817-5.00015-7     Document Type: Chapter

References (71)

1. Popper H. The role of the human pathologist in the management of drug induced hepatic injury. Hum Pathol 1975 Nov, 6(6):649-651.
2. Kleiner D.E. The pathology of drug-induced liver injury. Semin Liver Dis 2009 Nov, 29(4):364-372.
3. Goodman Z.D. Drug hepatotoxicity. Clin Liver Dis 2002 May, 6(2):381-397.
4. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009 Jun, 62(6):481-492.
5. Tang W. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2007 Jun, 3(3):407-420.
6. Labbe G., Pessayre D., Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008 Aug, 22(4):335-353.
7. Roenigk H.H., Auerbach R., Maibach H.I., Weinstein G.D. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988 Jul, 19(1 Pt 1):145-156.
8. Moreira R.K., Chopp W., Washington M.K. The concept of hepatic artery-bile duct parallelism in the diagnosis of ductopenia in liver biopsy samples. Am J Surg Pathol 2011 Mar, 35(3):392-403.
9. Nakanuma Y., Tsuneyama K., Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. J Hepatobiliary Pancreat Surg 2001, 8(4):303-315.
10. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009 Nov 25, 68(7):1086-1093.
11. Popper H., Rubin E., Cardiol D., Schaffner F., Paronetto F. Drug-induced liver disease: a penalty for progress. Arch Intern Med 1965 Feb, 115:128-136.
12. Zimmerman H.J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott Williams & Wilkins, Philadelphia. 2nd ed.
13. Suzuki A., Brunt E.M., Kleiner D.E., Miquel R., Smyrk T.C., Andrade R.J., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011 Jun 14, 54:931-939.
14. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008 Jul, 48(1):169-176.
15. Russo M.W., Scobey M., Bonkovsky H.L. Drug-induced liver injury associated with statins. Semin Liver Dis 2009 Nov, 29(4):412-422.
16. Dujovne C.A., Chan C.H., Zimmerman H.J. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med 1967 Oct 12, 277(15):785-788.
17. Benjamin S.B., Goodman Z.D., Ishak K.G., Zimmerman H.J., Irey N.S. The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology 1985 Nov-Dec, 5(6):1163-1171.
18. Aponte J., Petrelli M. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 1988 Dec, 31(12):1457-1464.
19. Kremer J.M., Lee R.G., Tolman K.G. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989 Feb, 32(2):121-127.
20. Sharp J.R., Ishak K.G., Zimmerman H.J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980 Jan, 92(1):14-19.
21. Bjornsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010 Jun, 51(6):2040-2048.
22. Lewis J.H., Mullick F., Ishak K.G., Ranard R.C., Ragsdale B., Perse R.M., et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990 Jan, 21(1):59-67.
23. Farah M., Al Rashidi A., Owen D.A., Yoshida E.M., Reid G.D. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 2008 Feb, 35(2):349-351.
24. Kleiner D.E. Granulomas in the liver. Semin Diagn Pathol 2006 Aug-Nov, 23(3-4):161-169.
25. Brown M., Schubert T. Phenytoin hypersensitivity hepatitis and mononucleosis syndrome. J Clin Gastroenterol 1986 Aug, 8(4):469-477.
26. Gan T.E., Van der Weyden M.B. Dapsone-induced infectious mononucleosis-like syndrome. Med J Aust 1982 Apr 17, 1(8):350-351.
27. Mullick F.G., Ishak K.G. Hepatic injury associated with diphenylhydantoin therapy. A clinicopathologic study of 20 cases. Am J Clin Pathol 1980 Oct, 74(4):442-452.
28. Suh N., Liapis H., Misdraji J., Brunt E.M., Wang H.L. Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients. Am J Surg Pathol 2007 Sep, 31(9):1403-1409.
29. Purtilo D.T., Sakamoto K. Epstein-Barr virus and human disease: immune responses determine the clinical and pathological expression. Hum Pathol 1981 Aug, 12(8):677-679.
30. Snover D.C., Horwitz C.A. Liver disease in cytomegalovirus mononucleosis: a light microscopical and immunoperoxidase study of six cases. Hepatology 1984 May-Jun, 4(3):408-412.
31. Larson A.M. Acetaminophen hepatotoxicity. Clin Liver Dis 2007 Aug, 11(3):525-548. [vi].
32. Clark R., Borirakchanyavat V., Davidson A.R., Thompson R.P., Widdop B., Goulding R., et al. Hepatic damage and death from overdose of paracetamol. Lancet 1973 Jan 13, 301(7794):66-70.
33. Holt M.P., Cheng L., Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008 Dec, 84(6):1410-1421.
34. Vuppalanchi R., Hayashi P.H., Chalasani N., Fontana R.J., Bonkovsky H., Saxena R., et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010 Nov, 32(9):1174-1183.
35. Puls F., Agne C., Klein F., Koch M., Rifai K., Manns M.P., et al. Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. Virchows Arch 2011 Jun, 458(6):709-716.
36. Velayudham L.S., Farrell G.C. Drug-induced cholestasis. Expert Opin Drug Saf 2003 May, 2(3):287-304.
37. Marinelli R.A., Lehmann G.L., Soria L.R., Marchissio M.J. Hepatocyte aquaporins in bile formation and cholestasis. Front Biosci 2011, 17:2642-2652.
38. Ludwig J., Kim C.H., Wiesner R.H., Krom R.A. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy?. Hepatology 1989 Feb, 9(2):215-218.
39. Lefkowitch J.H. Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and "cholangitis lenta.". Hum Pathol 1982 Jan, 13(1):19-24.
40. Ishak K.G. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981 May, 1(2):116-128.
41. Crawford A.R., Lin X.Z., Crawford J.M. The normal adult human liver biopsy: a quantitative reference standard. Hepatology 1998 Aug, 28(2):323-331.
42. Castellano G., Moreno-Sanchez D., Gutierrez J., Moreno-Gonzalez E., Colina F., Solis-Herruzo J.A. Caustic sclerosing cholangitis. Report of four cases and a cumulative review of the literature. Hepatogastroenterology 1994 Oct, 41(5):458-470.
43. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis. 2002, 22(2):185-194.
44. Stravitz R.T., Sanyal A.J. Drug-induced steatohepatitis. Clin Liver Dis 2003 May, 7(2):435-451.
45. Nyfors A., Poulsen H. Liver biopsies from psoriatics related to methotrexate therapy. 1. Findings in 123 consecutive non-methotrexate treated patients. Acta Pathol Microbiol Scand [A] 1976 May, 84(3):253-261.
46. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006 Jul, 5(4):567-583.
47. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett 2006 Oct 9, 580(23):5533-5540.
48. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995, 67(1):101-154.
49. Pessayre D., Mansouri A., Haouzi D., Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999, 15(6):367-373.
50. De Bus L., Depuydt P., Libbrecht L., Vandekerckhove L., Nollet J., Benoit D., et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol 2010 Sep, 6(3):322-326.
51. Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol 2003 Sep, 39(3):437-446.
52. Feaux de Lacroix W., Runne U., Hauk H., Doepfmer K., Groth W., Wacker D. Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment. Cancer Treat Rep 1983 Sep, 67(9):779-784.
53. Bismuth H., Sherlock D.J. Portasystemic shunting versus liver transplantation for the Budd-Chiari syndrome. Ann Surg 1991 Nov, 214(5):581-589.
54. DeLeve L.D., Shulman H.M., McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002 Feb, 22(1):27-42.
55. Karasawa T., Shikata T., Smith R.D. Peliosis hepatis. Report of nine cases. Acta Pathol Jpn 1979 May, 29(3):457-469.
56. Larrey D., Freneaux E., Berson A., Babany G., Degott C., Valla D., et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988 Sep, 29(9):1265-1269.
57. Mikkelsen W.P., Edmondson H.A., Peters R.L., Redeker A.G., Reynolds T.B. Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis). Ann Surg 1965 Oct, 162(4):602-620.
58. Shepherd P., Harrison D.J. Idiopathic portal hypertension associated with cytotoxic drugs. J Clin Pathol 1990 Mar, 43(3):206-210.
59. Wanless I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990 May, 11(5):787-797.
60. Reshamwala P.A., Kleiner D.E., Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006 Jul, 44(1):7-14.
61. Rubbia-Brandt L., Lauwers G.Y., Wang H., Majno P.E., Tanabe K., Zhu A.X., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010 Mar, 56(4):430-439.
62. Lefkowitch J.H., Lobritto S.J., Brown R.S., Emond J.C., Schilsky M.L., Rosenthal L.A., et al. Ground-glass, polyglucosan-like hepatocellular inclusions: a "new" diagnostic entity. Gastroenterology 2006 Sep, 131(3):713-718.
63. Torbenson M., Chen Y.Y., Brunt E., Cummings O.W., Gottfried M., Jakate S., et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006 Apr, 30(4):508-513.
64. Iancu T.C., Shiloh H., Dembo L. Hepatomegaly following short-term high-dose steroid therapy. J Pediatr Gastroenterol Nutr 1986 Jan, 5(1):41-46.
65. Klinge O., Bannasch P. The increase of smooth endoplasmatic reticulum in hepatocytes of human liver punctates. Verh Dtsch Ges Pathol 1968, 52:568-573.
66. Jezequel A.M., Librari M.L., Mosca P., Novelli G., Lorenzini I., Orlandi F. Changes induced in human liver by long-term anticonvulsant therapy. Functional and ultrastructural data. Liver 1984 Oct, 4(5):307-317.
67. Mathieu D., Kobeiter H., Cherqui D., Rahmouni A., Dhumeaux D. Oral contraceptive intake in women with focal nodular hyperplasia of the liver. Lancet 1998 Nov 21, 352(9141):1679-1680.
68. Scalori A., Tavani A., Gallus S., La Vecchia C., Colombo M. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002 Feb, 186(2):195-197.
69. Giannitrapani L., Soresi M., La Spada E., Cervello M., D'Alessandro N., Montalto G. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006 Nov, 1089:228-236.
70. Bioulac-Sage P., Rebouissou S., Thomas C., Blanc J.F., Saric J., Sa Cunha A., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007 Sep, 46(3):740-748.
71. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 Jun, 22(6):696-699.